Onat Kadioglu
Overview
Explore the profile of Onat Kadioglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kadioglu O, Saeed M, Mahmoud N, Azawi S, Mrasek K, Liehr T, et al.
Life Sci
. 2021 May;
284:119601.
PMID: 33991550
Aims: Epidermal growth factor receptor (EGFR) is not only involved in carcinogenesis, but also in chemoresistance. We characterized U87.MGΔEGFR glioblastoma cells with constitutively active EGFR due to deletion at the...
12.
Kadioglu O, Saeed M, Greten H, Efferth T
Comput Biol Med
. 2021 Apr;
133:104359.
PMID: 33845270
Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We...
13.
Kadioglu O, Saeed M, Mahmoud N, Azawi S, Mrasek K, Liehr T, et al.
Arch Toxicol
. 2021 Jan;
95(3):959-974.
PMID: 33515271
TP53 (p53) is a pivotal player in tumor suppression with fifty percent of all invasive tumors displaying mutations in the TP53 gene. In the present study, we characterized colon cancer...
14.
Kadioglu O, Saeed M, Mahmoud N, Hussein Azawi S, Rincic M, Liehr T, et al.
Life Sci
. 2020 Dec;
267:118922.
PMID: 33358905
Aims: We systematically characterized metastatic murine B16-F10 melanoma, a sub-line derived from murine melanoma B16-F1 cells. Materials And Methods: RNA-sequencing and network analyses (Ingenuity Pathway Analysis) were performed to identify...
15.
Saeed M, Kadioglu O, Greten H, Yildirim A, Mayr K, Wenz F, et al.
Invest New Drugs
. 2020 Dec;
39(3):670-685.
PMID: 33313992
Background Precision medicine and drug repurposing are attractive strategies, especially for tumors with worse prognosis. Glioblastoma is a highly malignant brain tumor with limited treatment options and short survival times....
16.
Kadioglu O, Saeed M, Munder M, Spuller A, Greten H, Efferth T
Biomed Pharmacother
. 2020 Sep;
131:110718.
PMID: 32932043
ATP-binding cassette (ABC) transporters mediate multidrug resistance in cancer. In contrast to DNA single nucleotide polymorphisms in normal tissues, the role of mutations in tumors is unknown. Furthermore, the significance...
17.
Kadioglu O, Saeed M, Greten H, Mayr K, Schrama D, Roos W, et al.
J Am Acad Dermatol
. 2020 Jul;
84(4):1086-1089.
PMID: 32707252
No abstract available.
18.
Abdelfatah S, Bockers M, Asensio M, Kadioglu O, Klinger A, Fleischer E, et al.
Phytomedicine
. 2020 Apr;
86:153196.
PMID: 32229058
Background: A major problem of cancer treatment is the development of multidrug resistance (MDR) to chemotherapy. MDR is caused by different mechanisms such as the expression of the ABC-transporters P-glycoprotein...
19.
Kadioglu O, Saeed M, Munder M, Spuller A, Greten H, Efferth T
Cells
. 2020 Jan;
9(2).
PMID: 31991926
The efficiency of chemotherapy drugs can be affected by ATP-binding cassette (ABC) transporter expression or by their mutation status. Multidrug resistance is linked with ABC transporter overexpression. In the present...
20.
Kadioglu O, Efferth T
Cells
. 2019 Oct;
8(10).
PMID: 31640190
P-glycoprotein (P-gp) is an important determinant of multidrug resistance (MDR) because its overexpression is associated with increased efflux of various established chemotherapy drugs in many clinically resistant and refractory tumors....